Due to the compounds plasma half-life of approximately 3.86.9 hours, twice-daily (BID) dosing may provide more sustained NNMT inhibition
Apr 2010;7(4):1508-19
Theres only one phase one trial thats registered right now, and its been registered since 2016, and nothing has been updated on that registration, so that tells you something as well
Zimmermann S, Steding G, Emmen JM, Brinkmann AO, Nayernia K, Holstein AF, Engel W, Adham IM (1999) Targeted disruption of the Insl3 gene causes bilateral cryptorchidism
Timing is a critical clue in determining the cause of the rash
Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells